QPPV.COM KNOWLEDGE ASSESSMENT

Garadacimab: Mechanism, Clinical Use and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Garadacimab: FXIIa Inhibition, Hereditary Angioedema and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient experiences repeated severe attacks despite documented injections. Which approach best evaluates whether this represents inadequate preventive response?

Count the attacks and conclude treatment failure without reviewing the clinical context. Review the attack phenotype, baseline burden, diagnosis, exposure, adherence, interruptions, intercurrent factors and rescue treatment. Exclude the events because attacks cannot occur during effective prophylaxis. Attribute the attacks to waning drug effect if they occur at any point during a monthly interval.

Question 2 of 10 A clinician is explaining the EU-authorised role of garadacimab to a patient. Which statement is most accurate?

It is intended to treat an acute attack and removes the need for rescue medication. It is routine prevention of recurrent HAE attacks in adults and adolescents aged 12 years and older. It is authorised only for patients whose HAE is associated with normal C1-INH. It is used to prevent attacks only after an acute attack has been treated with garadacimab.

Question 3 of 10 A team is evaluating an apparent increase in reports of breakthrough attacks over time. Which analysis plan is most consistent with the article?

Interpret the increase as reduced effectiveness unless the total number of reports falls. Stratify by relevant characteristics such as HAE subtype, age, baseline burden, prophylaxis duration and prior preventive therapy where data permit. Exclude reports from patients who used rescue medicine because rescue use makes the attack uninterpretable. Combine all reports and compare raw counts between periods without considering patient mix.

Question 4 of 10 A reviewer is interpreting the pivotal trial’s lower average monthly attack rate in the garadacimab group than in the placebo group. Which conclusion is appropriately supported?

Every treated patient should be expected to remain attack-free. The result supports efficacy in the studied population but does not guarantee an individual response or establish equal efficacy in every HAE subtype. The result establishes efficacy for all HAE forms, including populations not represented in the trial. The result shows that attacks during treatment cannot be genuine HAE attacks.

Question 5 of 10 Why should a case-processing record include rescue medicines and other preventive HAE therapies?

They provide treatment-context information relevant to interpreting the event and response. Their use automatically confirms that garadacimab was ineffective. They establish the patient’s C1-INH level without laboratory testing. They eliminate the need to record injection dates.

Question 6 of 10 A signal review raises the possibility of loss of effect in some patients. How should the team communicate this finding before causality is established?

Present loss of effect as a confirmed product effect because multiple reports exist. Describe it as a signal hypothesis and identify evidence that could confirm or weaken it. Avoid documenting the hypothesis until a label change has been approved. Treat the hypothesis as established whenever attacks occur after an injection.

Question 7 of 10 For a patient with HAE and normal C1-INH, which response-assessment approach is most consistent with the product information described in the article?

Assume the response is equivalent to that in HAE associated with low or dysfunctional C1-INH. Consider discontinuation if there is no reduction in attacks after three months. Assess response only after one year because earlier attack patterns are not informative. Continue indefinitely if any attack occurs, since an attack confirms ongoing drug activity.

Question 8 of 10 During an inspection, which approach to a series of reported breakthrough attacks would best demonstrate clinically contextualised product-performance evaluation?

Count each coded attack and escalate based on the total alone. Assess the events against baseline burden, phenotype, actual exposure and adherence before interpreting a possible pattern. Exclude attacks that occurred after a delayed injection from review. Treat every reported attack as proof of a new safety risk.

Question 9 of 10 A company proposes treating an internal follow-up form as a legal requirement for every garadacimab case. Which governance interpretation is most appropriate?

Any recommended operational field automatically becomes a legal requirement. Internal controls may support case assessment, but should not be presented as legal requirements unless an applicable source establishes that status. Operational recommendations should never be used in pharmacovigilance procedures. A follow-up form replaces the need to comply with the current product information.

Question 10 of 10 A patient reports recurring injection-site symptoms after monthly administration. Which documentation is most useful for assessing the reported reaction?

Record only that an injection-site reaction occurred. Describe onset, duration and severity, and whether the symptoms recur with subsequent injections. Record only the injection route because all other details are redundant. Classify the reaction as serious if it recurs, regardless of its clinical features.

Garadacimab: Mechanism, Clinical Use and Pharmacovigilance Assessment

Cookie Settings